Regeneron Pharmaceuticals Inc 2021 SR
The report highlights Regeneron's progress in 2021 across three focus areas: improving lives, fostering integrity, and building sustainable communities. Key achievements include reinvesting $2.9 billion in R&D, advancing a pipeline of over 30 clinical candidates, and delivering 2.8 million doses of REGEN-COV to the U.S. government. The company grew its workforce by 14% and launched a new DEI strategy. Environmentally, Regeneron achieved 20% renewable electricity globally and maintained 100% renewable electricity at its Irish site, while continuing to divert 100% of waste from landfills.
Company: Regeneron Pharmaceuticals Inc
Sector: Manufacturing
Country: United States
Year: 2021
Type: SR
Pages: 86
Back to company
Regeneron Pharmaceuticals Inc
Responsibility Report
The report highlights Regeneron's progress in 2021 across three focus areas: improving lives, fostering integrity, and building sustainable communities. Key achievements include reinvesting $2.9 billion in R&D, advancing a pipeline of over 30 clinical candidates, and delivering 2.8 million doses of REGEN-COV to the U.S. government. The company grew its workforce by 14% and launched a new DEI strategy. Environmentally, Regeneron achieved 20% renewable electricity globally and maintained 100% renewable electricity at its Irish site, while continuing to divert 100% of waste from landfills.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees